Funded Tech Companies
Nucleome Therapeutics
Headquartered in Oxford, Nucleome Therapeutics has funding from Pfizer Venture Investments, M Ventures and British Patient Capital.
Company Overview
Company Name
Nucleome Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Suite C, Second Floor, Schrodinger Building, Oxford Science
Oxford, OX4 4GE
UK
Oxford, OX4 4GE
UK
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Nucleome has the unique ability to discover and validate first-in-class targets through genetics in the dark genome. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights. The dark matter, or non-coding regions of DNA, makes up around 98% of our DNA and we now know that 90% of disease associated genetic variations originate here. Instead of coding for proteins, this dark genome has a regulatory role, it controls gene expression. It acts like an instruction processor, turning genes on and off at the right time and levels. This enables our genetic code to be translated into the hundreds of cell types that exist.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
10/19/2022
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Danuta Jeziorska
Chief Financial Officer
Phil Boyd
VP - Operations
Dina Anderson
Company Investors
- Pfizer Venture Investments
- M Ventures
- British Patient Capital
- Johnson & Johnson Innovation
- Oxford Sciences Innovations
Browse more funded tech companies:
Share this article
About Our VC & M&A Database
The company data above is provided by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs